HER2-LOW OR HER2-ULTRALOW

Clinical trials for HER2-LOW OR HER2-ULTRALOW explained in plain language.

Never miss a new study

Get alerted when new HER2-LOW OR HER2-ULTRALOW trials appear

Sign up with your email to follow new studies for HER2-LOW OR HER2-ULTRALOW, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Double-Barreled drug attack targets Hard-to-Treat breast cancer

Disease control Not yet recruiting

This trial is studying a combination of two targeted drugs, patritumab deruxtecan and trastuzumab deruxtecan, for people with a specific type of advanced breast cancer that is hormone receptor positive and has low or ultra-low levels of a protein called HER2. The study aims to fi…

Matched conditions: HER2-LOW OR HER2-ULTRALOW

Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control

Last updated Jul 16, 2026 00:00 UTC

HER2-LOW OR HER2-ULTRALOW

Get alerted when new HER2-LOW OR HER2-ULTRALOW trials appear

Double-Barreled drug attack targets Hard-to-Treat breast cancer